REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 27th, 2021 • Marizyme Inc • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 21, 2021, among Marizyme, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
ContractMarizyme Inc • December 27th, 2021 • Pharmaceutical preparations • New York
THIS NOTE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT SECURED BY SUCH SECURITIES.
ContractMarizyme Inc • December 27th, 2021 • Pharmaceutical preparations
THIS WARRANT HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 27th, 2021 • Marizyme Inc • Pharmaceutical preparations • New York
UNIT PURCHASE AGREEMENTUnit Purchase Agreement • December 27th, 2021 • Marizyme Inc • Pharmaceutical preparations • New York
This Unit Purchase Agreement (as amended, supplemented, restated and/or modified from time to time, this “Agreement”) is entered into as of December , 2021, by and among Marizyme, Inc., a Nevada corporation (the “Company”), and each investor identified on Appendix A hereto (each, including its successors and assigns, an “Investor” and collectively, the “Investors”).
MARIZYME, INC. CONSULTING AGREEMENTConsulting Agreement • December 27th, 2021 • Marizyme Inc • Pharmaceutical preparations • Florida
THIS CONSULTING AGREEMENT (this “Agreement”) is entered into effective as of December 21, 2021 (“Effective Date”) by and among Marizyme, Inc. a Nevada corporation (the “Company”), AAT Services Inc., a corporation incorporated pursuant to the laws of British Columbia, Canada (“AAT”) and George Kovalyov, an individual (“Principal” and together with AAT, the “Consultant”). The Company together with the Consultant, the “Parties,” and each individually, a “Party”.
EXCHANGE AGREEMENTExchange Agreement • December 27th, 2021 • Marizyme Inc • Pharmaceutical preparations • Nevada
This EXCHANGE AGREEMENT (this “Agreement”), dated as of December , 2021, is by and between Marizyme, Inc., a Nevada corporation (the “Company”) and the person executing a copy of this Agreement for the benefit of the Company as set forth on the signature page hereto (the “Holder”).
